Abstract 1522P
Background
Preoperative chemoradiotherapy (CRT) is the current standard treatment for locally advanced oesophageal cancer in the world. In previous single-arm clinical trials, neoadjuvant camrelizumab (anti-PD-1 antibody) plus chemotherapy showed durable antitumor activity with a manageable safety profile in patients with locally advanced oesophageal squamous cell carcinoma (ESCC). In this multicenter, randomized, open-label, phase II REVO trial, we compared immunochemotherapy (ICT) with concurrent CRT as neoadjuvant therapy in patients with resectable thoracic ESCC using a non-inferiority design.
Methods
Patients were randomly assigned to two to four 21-day cycles of intravenous camrelizumab (200 mg, day 1) plus albumin-bound paclitaxel (125 mg/m2, days 1 and 8) and cisplatin (75 mg/m2, day 1), or two 21-day cycles of albumin-bound paclitaxel and cisplatin combined with concurrent radiotherapy (36-40Gy in 20 fractions, 5 days per week), followed by surgery. The primary endpoint was pathological complete response (pCR) rate.
Results
Between September 2021 and March 2023, 85 patients had been enrolled, and the enrolment is still ongoing. As of April 6, 2023, 32 of 41 and 28 of 44 patients underwent surgery in the ICT and CRT groups, respectively. All patients achieved R0 resection. The pCR (ypT0N0) and major pathological response (MPR) rates were 40.6% (13/32) and 62.5% (20/32) in the ICT group and 35.7% (10/28) and 71.4% (20/28) in the CRT group, respectively. The incidence of grade ≥3 treatment-related adverse events (TRAEs) was 22.0% in the ICT group and 31.8% in the CRT group. The most common grade ≥3 TRAE was decreased lymphocyte count (14.6%) in the ICT group, and decreased lymphocyte count (18.2%) and decreased platelet count (6.8%) in the CRT group. One patient in the CRT group died due to pneumonia after surgery.
Conclusions
The current results suggest that neoadjuvant camrelizumab plus chemotherapy is non-inferior to concurrent CRT for patients with locally advanced ESCC, with better safety. The final results and long-term survival will be reported in the future.
Clinical trial identification
NCT05007145.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21